Which hedge funds own LXEO? LEXEO THERAPEUTICS INC, Q2 2026 13F holders
33 tracked hedge funds disclosed a position in LXEO (LEXEO THERAPEUTICS INC) in their Q2 2026 13F filings, worth $266.4m in total. The largest holder by portfolio weight is Affinity Asset Advisors, LLC at 1.3% of its book. 7 opened a new position this quarter: Verdad Advisers, LP, Spark Investment Management LLC, Trexquant Investment LP, Prelude Capital Management, LLC. 6 exited: Octagon Capital Advisors LP, Point72 Asset Management, L.P., Y-Intercept (Hong Kong) Ltd.
- 33
- Holders Tracked managers whose filing for the quarter reports a long equity position in the security.
- 7
- New this quarter Holders whose previous filing (at most two quarters earlier) did not report the security.
- 6
- Exited this quarter Tracked managers whose previous filing reported the security and whose filing for the quarter does not.
- $3.4m
- Inflow, new holders Combined value of the positions the new holders reported for the quarter.
- $18.2m
- Outflow, exits Combined value the exiting managers reported for the security in their previous filing.
- $266m
- Combined value Sum of the holders' reported positions in the security.
- 2.7%
- Share of managers holding Holders as a share of tracked managers filing for that quarter. Comparable across the 2024 coverage expansion, where the raw holder count is not.
Holders, Q2 2026
Exited since the previous filing
| Octagon Capital Advisors LP | 0.7% | $6.3m |
| Point72 Asset Management, L.P. | 0.02% | $9.6m |
| Y-Intercept (Hong Kong) Ltd | 0.02% | $818k |
| Gsa Capital Partners LLP | 0.01% | $197k |
| Schonfeld Strategic Advisors LLC | 0.0% | $139k |
| Two Sigma Investments, LP | 0.0% | $1.0m |
Ownership over time
Who discovered LXEO first? Beta
| Affinity Asset Advisors, LLC | Q2 2025 | +1.4 pts |
| Frazier Life Sciences Management, L.P. | Q2 2025 | +0.1 pts |
| ADAR1 Capital Management, LLC | Q3 2025 | −0.1 pts |
| Vestal Point Capital, LP | Q2 2024 | −0.7 pts |
| Paradigm Biocapital Advisors LP | Q4 2025 | −0.7 pts |
| Octagon Capital Advisors LP | Q4 2025 | −0.9 pts |
Split-adjusted quarter-end prices, excluding dividends. They describe the stock while each manager held it, not the return it earned.